Drug Trial Radar · NCT02600429
Assessment of the Safety and Efficacy Study of RGN-259 Ophthalmic Solutions for Neurotrophic Keratopathy : SEER-1
Last checked: Nov 19, 2026Latest source record: Aug 30, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
18
Actual
Start
Sep 17, 2015
Primary completion
Nov 20, 2019
Study completion Mar 9, 2020
Sponsor
- Lead sponsor
- ReGenTree, LLCIndustry
- Sponsor type
- Industry
- First posted
- Nov 9, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to assess the safety and efficacy of RGN-259 Ophthalmic Solution compared to placebo for the treatment of NK.
Conditions
- Neurotrophic Keratopathy
Interventions
RGN-259Drug
A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into affected eye(s), five times a day for 4 weeks.
PlaceboDrug
It is composed of the same excipients as RGN-259 but does not contain Tβ4
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Subjects Achieving Complete Healing at Day 29.Time frame: 29 days after first dosing
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
Hull Eye Center
Lancaster, California
Vision Institute
Colorado Springs, Colorado
Eye Center of Northern Colorado
Fort Collins, Colorado
Insight Vision Group
Parker, Colorado
Medical Faculty Associates, Inc.
Washington D.C., District of Columbia
Midwest Cornea Associates, LLC
Indianapolis, Indiana
Koffler Vision Group
Lexington, Kentucky
Richard Eiferman, MD, PSC
Louisville, Kentucky
The Eye Care Institute
Louisville, Kentucky
Central Maine Eye Care
Lewiston, Maine
Black Hills Regional Eye Institute
Rapid City, South Dakota
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.